| Literature DB >> 31118993 |
Mieszko Kozikowski1, Bartłomiej Zagożdżon1, Magdalena Gola2, Jakub Dobruch1.
Abstract
INTRODUCTION: The Prostate Imaging Reporting and Data System (PI-RADS) was mainly developed for the purposes of prostate cancer (PCa) detection. However, its widespread use suggests that it may play a role in a preoperative workup prior to endoscopic radical prostatectomy (ERP). AIM: To evaluate the prognostic value of PI-RADS in predicting extraprostatic extension (EPE) and its influence on surgical planning of ERP.Entities:
Keywords: decision-making; mini-invasive surgery; multiparametric magnetic resonance imaging; neurovascular bundle; prostate cancer; radical prostatectomy
Year: 2019 PMID: 31118993 PMCID: PMC6528114 DOI: 10.5114/wiitm.2019.83869
Source DB: PubMed Journal: Wideochir Inne Tech Maloinwazyjne ISSN: 1895-4588 Impact factor: 1.195
Clinical characteristics of 154 men included in the study
| Parameter | Value |
|---|---|
| Age, mean ± SD [years] | 63.7 ±6.17 |
| PSA, mean ± SD [ng/ml] | 10.7 ±13.2 |
| prostate volume, mean ± SD [ml] | 39.9 ±18.7 |
| PSAD, mean ± SD [ng/ml2] | 0.31 ±0.46 |
| GS in biopsy: | |
| ≤ 6 | 56 (36.3%) |
| 7 | 74 (48.1%) |
| ≥ 8 | 24 (15.6%) |
| cT: | |
| cT1 | 57 (37.0%) |
| cT2 | 91 (59.1%) |
| ≥ cT3 | 6 (3.9%) |
| PI-RADS assessment category | |
| PI-RADS ≤ 2 | 89 (28.9%) |
| PI-RADS 3 | 44 (14.3%) |
| PI-RADS 4 | 108 (35.1%) |
| PI-RADS 5 | 67 (21.7%) |
| GS in histopathology: | |
| ≤ 6 | 49 (31.8%) |
| 7 | 84 (54.6%) |
| ≥ 8 | 21 (13.6%) |
| pT: | |
| ≤ pT2 | 101 (65.6%) |
| ≥ pT3 | 53 (34.4%) |
| Surgical margins’ status: | |
| PSM – | 134 (87.0%) |
| PSM + | 20 (13.0%) |
SD – standard deviation, PSA – prostate-specific antigen, PSAD – prostate specific antigen density, GS – Gleason score, cT – clinical stage in digital rectal examination, PI-RADS – Prostate Imaging Reporting and Data System, pT – pathologic stage, PSM – positive surgical margin. Unless otherwise specified all variables were calculated in per patient analysis.
Per side analysis.
Staging performance of mpMR and PI-RADS
| Staging method | AUC | Threshold | SE (%) | SP (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|
| PI-RADS | 0.615 | PI-RADS 5 | 39.4 | 83.5 | 41.8 | 82.2 |
| mpMRI | 0.552 | iT2c/T3 | 18.3 | 92.0 | 40.6 | 79.0 |
mpMRI – multiparametric magnetic resonance imaging, PI-RADS – Prostate Imaging Reporting and Data System, AUC – area under the curve, SE – sensitivity, SP – specificity, PPV – positive predictive value, NPV – negative predictive value.
Per side analysis.
DeLong’s test for two correlated ROC curves: p = 0.0362.
Figure 1Comparison of staging performance of mpMRI and PI-RADS using ROC
PI-RADS is shown as the blue curve, mpMRI as the red curve.
Clinical variables associated with side-specific EPE
| Parameter | Analysis | |||
|---|---|---|---|---|
| Univariate | Multivariate | |||
| OR | OR | |||
| PSA | 1.04 | 0.0032 | 1.12 | 0.0081 |
| PSAD | 2.30 | 0.0216 | – | – |
| GS in biopsy | 1.07 | 0.0008 | 1.72 | 0.0720 |
| cT in DRE | 1.71 | 0.0483 | 1.08 | 0.8310 |
| PI-RADS (≤ 4 vs. 5) | 3.31 | 0.0001 | 3.40 | 0.0038 |
| iT in mpMRI | 1.22 | 0.0126 | 1.03 | 0.9509 |
p < 0.1
p < 0.05
p < 0.01
p < 0.001. – Not included in the multivariate model because it is a combination of other variables. PCa – prostate cancer, OR – odds ratio, PSA – prostate-specific antigen, PSAD – prostate-specific antigen density, DRE – digital rectal examination, PI-RADS – Prostate Imaging Reporting and Data System, mpMRI – multiparametric magnetic resonance imaging.
Per side analysis.
Figure 2Comparison of staging performance of models incorporating mpMRI or PI-RADS using ROC
The model using PI-RADS is shown as the blue curve, the model using mpMRI as the red curve.
Modification of surgical plan related to EPE detection in mpMRI and PI-RADS score
| Srgical plan | Unchanged ( | Changed ( | |
|---|---|---|---|
| PI-RADS: | 0.0277 | ||
| ≤ 4 | 158 (75.5%) | 83 (86.5%) | |
| 5 | 54 (25.5%) | 13 (13.5%) | |
| iT in mpMRI: | 0.0167 | ||
| EPE – | 182 (85.8%) | 92 (95.8%) | |
| EPE + | 30 (14.2%) | 4 (4.2%) | |
| NVB: | < 0.001 | ||
| Preservation | 102 (48.1%) | 85 (88.5%) | |
| Resection | 110 (51.9%) | 11 (11.5%) | |
| pT: | 0.8540 | ||
| ≤ pT2 | 162 (76.4%) | 75 (78.1%) | |
| ≥ pT3 | 50 (23.6%) | 21 (21.9%) | |
| Surgical margin: | 0.1960 | ||
| PSM – | 187 (88.2%) | 90 (93.8%) | |
| PSM + | 25 (11.8%) | 6 (6.2%) | |
p < 0.05
**p < 0.01
p < 0.001. PI-RADS – Prostate Imaging Reporting and Data System, mpMRI – multiparametric magnetic resonance imaging, pT – pathological tumor staging, PSM – positive surgical margin.
Per side analysis.
PI-RADS score related to local staging and surgical margins status
| Parameter | PI-RADS ≤ 2 ( | PI-RADS 3 ( | PI-RADS 4 ( | PI-RADS 5 ( |
|---|---|---|---|---|
| pT | ||||
| pT2 | 72 (80.9%) | 29 (65.9%) | 97 (89.8%) | 39 (58.2%) |
| pT3 | 17 (19.1%) | 15 (34.1%) | 11 (10.2%) | 28 (41.8%) |
| PSM | ||||
| PSM – | 82 (92.1%) | 37 (84.1%) | 104 (96.3%) | 54 (80.6%) |
| PSM + | 7 (7.9%) | 7 (15.9%) | 4 (3.7%) | 13 (19.4%) |
| NVB | ||||
| Preservation | 75 (84.3%) | 27 (61.4%) | 67 (62.0%) | 18 (26.9%) |
| Resection | 14 (15.7%) | 17 (38.6%) | 41 (38.0%) | 49 (73.1%) |
*p < 0.05
p < 0.01
p < 0.001. PI-RADS – Prostate Imaging Reporting and Data System, pT – pathological tumor staging, PSM – positive surgical margin.
per side analysis.